

Technology Appraisal Committee A Interests Register

Topic: Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [ID1680]

Publication Date: 17/02/2021

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Steve Edwards	TA Committee A Member	Non-financial professional & personal interest	Member of the Evidence Review Group for this topic.	NA	19/10/2020	NA	It was agreed that this declaration would prevent Dr Edwards from participating in this section of the meeting and he was asked to leave the meeting for the duration of the item.
Dr Alice Turner	TA Committee A Member	Indirect interest	Consultancy work for GSK in area of COPD (i.e. non cancer)	NA	19/10/2020	NA	It was agreed that this declaration would not prevent Dr Turner from participating in this section of the meeting.
Dr Shibani Nicum	Clinical Expert	Direct financial interest	Taken part in remunerated advisory boards, received travel support (expenses) and currently has academic research collaborations which have been part funded by pharmaceutical companies including AstraZeneca. Tesaro, GSK, Roche, Abbvie.	NA	16/09/2020	NA	It was agreed that these declarations would not prevent Dr Nicum from participating in this section of the meeting.

Professor Charlie Gourley	Clinical Expert	Direct financial interests	<p>GlaxoSmithKline (and previously Tesaro); owners of niraparib: Financial recompense for sitting on advisory boards and lecturing (start date unknown; ongoing commitments).</p> <p>AstraZeneca and GSK (co-owners of the competitor agent olaparib): Financial recompense for sitting on advisory boards and lecturing (start date unknown; ongoing commitments).</p> <p>Clovis (owners of competitor agent rucaparib): Financial recompense for sitting on advisory boards and lecturing (start date unknown; ongoing commitments).</p> <p>Roche (owners of bevacizumab): Financial recompense for sitting on advisory boards and lecturing (start date unknown).</p> <p>Nucana: Financial recompense for sitting on advisory boards and lecturing (start date unknown; ceased over 24 months ago).</p>	NA	28/09/2020	NA	It was agreed that these declarations would not prevent Professor Gourley from participating in this section of the meeting.
---------------------------	-----------------	----------------------------	--	----	------------	----	--

			<p>Sierra Oncology: Financial recompense for sitting on advisory boards (start date unknown; ceased 24 months ago).</p> <p>Foundation One (start date unknown; ceased over 24 months ago).</p> <p>Cor2Ed: Financial recompense for providing educational material and lecturing (start date unknown; ceased 6 months ago).</p>				
Professor Charlie Gourley	Clinical Expert	Direct non-financial interests	<p>GlaxoSmithKline/Tesaro: funding to my institution for participation in the PRIMA trial (ongoing).</p> <p>AstraZeneca/MSD: funding to my institution for participation in a number of olaparib trials (ongoing).</p> <p>Novartis: funding to my institution for clinical trial participation (ongoing).</p> <p>Aprea: funding to my institution for clinical trial participation (ongoing).</p> <p>Nucana: funding to my institution for clinical trial participation (ongoing).</p>	NA	28/09/2020	NA	It was agreed that these declarations would not prevent Professor Gourley from participating in this section of the meeting.

Professor Charlie Gourley	Clinical Expert	Indirect interests	<p>Named co-inventor on five patents related to ovarian cancer biomarkers:</p> <ul style="list-style-type: none"> - issued: PCT/US2012/040805 - pending: PCT/GB2013/053202, 1409479.1, 1409476.7 and 1409478.3 	NA	28/09/2020	NA	It was agreed that this declaration would not prevent Professor Gourley from participating in this section of the meeting.
---------------------------	-----------------	--------------------	--	----	------------	----	--